1st prescriptions for ruxolitinib phosphate cream, a vitiligo treatment, issued in China's Greater Bay Area.

China Medical System Holdings Limited (CMS) announced the issuance of the first prescriptions for ruxolitinib phosphate cream, a treatment for vitiligo, in the Greater Bay Area. Approved by Macau's Pharmaceutical Administration on April 11, 2024, and by Guangdong on August 19, it targets non-segmental vitiligo in patients aged 12 and older. If approved in mainland China, it would be the first prescription drug for vitiligo repigmentation there.

October 18, 2024
5 Articles